A Phase 2/3 interventional study of Nivolumab and Oxaliplatin in Colorectal Cancer, sponsored by Bristol-Myers Squibb. Completed at 49 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by Bristol-Myers Squibb · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing nivolumab in Colorectal Neoplasms — 7 open to participants now, 13 under way, 1 of them phase 3. Nivolumab · Colorectal Neoplasms.
Among the 38 studies testing nivolumab in Colorectal Neoplasms, this one is the 7th largest by enrollment, is one of 4 that started in 2018, is the only one in phase 2/3, and was the 8th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →7 of the 38 studies testing nivolumab in Colorectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Gruppo Oncologico del Nord-Ovest · Sites in Italy
Ages 18+
GERCOR - Multidisciplinary Oncology Cooperative Group · Sites in France
Ages 18+
Blokhin's Russian Cancer Research Center · Sites in Russia
Ages 18+
Fred Hutchinson Cancer Center · Sites in Uganda
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 29 · Phase 3 4
First in 2006; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 196 is above the median of 76 across 4,802 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 49 across the 38 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 38 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
29 studies in Colorectal Neoplasms by Bristol-Myers Squibb: 4 open now, 9 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, this one is the 13th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2018, is one of 2 in phase 2/3, and was the 14th registered.
Bristol-Myers Squibb’s Colorectal Neoplasms studies by the year they started, since 2002.
3 of the studies testing nivolumab in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04730544GERCOR - Multidisciplinary Oncology Cooperative GroupTwo Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. | 2027-04 |
| NCT05845450Gruppo Oncologico del Nord-OvestPre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | 2027-05 |
| NCT06265285Mayo ClinicComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | 2027-05-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies testing nivolumab in Colorectal Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 29 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This purpose of this study is to evaluate nivolumab (BMS-936558) in combination with standard of care (SOC) chemotherapy with bevacizumab for the treatment of first-line metastatic colorectal cancer (mCRC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nivo + SOC
Biological: Nivolumab · Drug: Oxaliplatin · Drug: Leucovorin · Drug: Fluorouracil · Drug: Bevacizumab
SOC
Drug: Oxaliplatin · Drug: Leucovorin · Drug: Fluorouracil · Drug: Bevacizumab
Specified dose on specified days
Also known as: BMS-936558, Opdivo
Specified dose on specified days
Specified dose on specified days
Also known as: Calcium Folinate
Specified dose on specified days
Specified dose on specified days
Also known as: Avastin
Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)
Progression Free Survival (PFS) is defined as the time from randomization to the date of the first documented progression, as determined by BICR (per RECIST 1.1), or death due to any cause, whichever occurs first. Baseline tumor assessment is defined as tumor scans prior to or on randomization date. Participants who did not have documented progression per BICR and who did not die or participants who started any subsequent anti-cancer therapy without a prior reported progression per BICR will be censored at the date of the last tumor assessment on or prior to initiation of the subsequent anticancer therapy, if any. Participants who die without a reported prior progression per BICR will be considered to have progressed on the date of death. Participants who did not have any baseline or post baseline tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date.
Time frame: From randomization to up to the date of the first documented progression (up to 16 months)
Progression Free Survival (PFS) Per Investigator Assessment
Progression Free Survival (PFS) is defined as the time from randomization to the date of the first documented progression, as determined by Investigator Assessment, or death due to any cause, whichever occurs first. Baseline tumor assessment is defined as tumor scans prior to or on randomization date. Participants who did not have documented progression per Investigator Assessment and who did not die or participants who started any subsequent anti-cancer therapy without a prior reported progression will be censored at the date of the last tumor assessment on or prior to initiation of the subsequent anticancer therapy, if any. Participants who die without a reported prior progression per Investigator Assessment will be considered to have progressed on the date of death. Participants who did not have any baseline or post baseline tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date.
Time frame: From randomization up to the date of the first documented progression (up to approximately 44 months)
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)
ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). BOR is defined as the best response designation as determined by BICR per RECIST 1.1, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of subsequent anticancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.
Time frame: From the date of randomization up to the date of objectively documented progression or the date of subsequent anticancer therapy, whichever occurs first (up to approximately 44 months)
Objective Response Rate (ORR) Per Investigator Assessment
ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). BOR is defined as the best response designation as determined by tumor assessments by the Investigator per RECIST 1.1, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of subsequent anticancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.
Time frame: From the date of randomization up to the date of objectively documented progression or the date of subsequent anticancer therapy, whichever occurs first (up to approximately 44 months)
Duration of Response (DoR) Per Blinded Independent Central Review (BICR)
Duration of objective response (DoR) is defined as the time between the date of first confirmed complete response (CR) or partial response (PR) to the date of the first documented tumor progression as assessed by the BICR based on RECIST 1.1 criteria or death due to any cause, whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.
Time frame: From randomization up to the date of the first documented progression (per RECIST 1.1) or death due to any cause, whichever occurs first (up to 44 months)
Duration of Response (DoR) Per Investigator Assessment
Duration of objective response (DoR) is defined as the time between the date of first confirmed complete response (CR) or partial response (PR) to the date of the first documented tumor progression as assessed by the investigator based on RECIST 1.1 criteria or death due to any cause, whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.
Time frame: From randomization up to the date of the first documented progression (per RECIST 1.1) or death due to any cause, whichever occurs first (up to 44 months)
Time to Objective Response Per Blinded Independent Central Review (BICR)
Time to objective response (TTR) is defined as the time from the randomization date to the date of the first confirmed complete response (CR) or partial response (PR) as assessed by BICR. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm. TTR is derived for responders only.
Time frame: From the randomization date up to the date of the first confirmed CR or PR (up to approximately 44 months)
Time to Objective Response Per Investigator Assessment
TTR is defined as the time from the randomization date to the date of the first confirmed complete response (CR) or partial response (PR) as assessed by investigator. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm. TTR is derived for responders only.
Time frame: From the randomization date up to the date of the first confirmed CR or PR (up to 44 months)
Overall Survival (OS)
Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For those without documentation of death, OS will be censored on the last date the participant was known to be alive.
Time frame: From the date of randomization up to the date of death (up to 44 months)
Number of Participants With Adverse Events (AEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
Time frame: From first dose to 30 days post last dose (up to 45 months)
Number of Participants With Serious Adverse Events (SAEs)
Number of participants with any grade of serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine safety and tolerability. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From first dose to 30 days post last dose (up to 45 months)
Number of Participants Experiencing Death
The number of participants who died during the treatment period
Time frame: From first dose up to 6 weeks post last dose (up to 46 months)
Number of Participants With Laboratory Abnormalities in Specific Liver Tests
The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal
Time frame: From first dose up to 30 days post last dose (up to 45 months)
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal
Time frame: From first dose up to 30 days post last dose (up to 45 months)
Disease Control Rate (DCR) Per Blinded Independent Central Review (BICR)
Disease Control Rate (DCR) is defined as the percentage of participants whose Best Overall Response (BOR) is complete response (CR) or partial response (PR) or stable disease (SD). CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.
Time frame: From the date of randomization up to the date of objectively documented progression or the date of subsequent anticancer therapy, whichever occurs first (up to approximately 44 months)
Disease Control Rate (DCR) Per Investigator
Disease Control Rate (DCR) is defined as the percentage of participants whose Best Overall Response (BOR) is complete response (CR) or partial response (PR) or stable disease (SD). CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.
Time frame: From the date of randomization up to the date of objectively documented progression or the date of subsequent anticancer therapy, whichever occurs first (up to approximately 44 months)
| Milestone | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Started | 127 | 68 |
| Completed | 123 | 62 |
| Not completed | 4 | 6 |
| Withdrew: Other reasons | 1 | 0 |
| Withdrew: Participant no longer meets study criteria | 2 | 3 |
| Withdrew: Participant withdrew consent | 1 | 3 |
| Milestone | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Started | 123 | 62 |
| Completed | 9 | 0 |
| Not completed | 114 | 62 |
| Withdrew: Participant withdrew consent | 4 | 3 |
| Withdrew: Participant request to discontinue study treatment | 8 | 10 |
| Withdrew: Adverse event unrelated to study drug | 5 | 2 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Study drug toxicity | 10 | 5 |
| Withdrew: Disease progression | 75 | 29 |
| Withdrew: Not reported | 1 | 0 |
| Withdrew: Other reasons | 3 | 2 |
| Withdrew: Poor/non-compliance | 2 | 0 |
| Withdrew: Maximum clinical benefit | 5 | 9 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Administrative reasons by sponsor | 1 | 0 |
Progression Free Survival (PFS) is defined as the time from randomization to the date of the first documented progression, as determined by BICR (per RECIST 1.1), or death due to any cause, whichever occurs first. Baseline tumor assessment is defined as tumor scans prior to or on randomization date. Participants who did not have documented progression per BICR and who did not die or participants who started any subsequent anti-cancer therapy without a prior reported progression per BICR will be censored at the date of the last tumor assessment on or prior to initiation of the subsequent anticancer therapy, if any. Participants who die without a reported prior progression per BICR will be considered to have progressed on the date of death. Participants who did not have any baseline or post baseline tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date.
| Months | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR) | 11.86 (8.94 to 15.70) | 11.93 (10.09 to 12.19) |
Progression Free Survival (PFS) is defined as the time from randomization to the date of the first documented progression, as determined by Investigator Assessment, or death due to any cause, whichever occurs first. Baseline tumor assessment is defined as tumor scans prior to or on randomization date. Participants who did not have documented progression per Investigator Assessment and who did not die or participants who started any subsequent anti-cancer therapy without a prior reported progression will be censored at the date of the last tumor assessment on or prior to initiation of the subsequent anticancer therapy, if any. Participants who die without a reported prior progression per Investigator Assessment will be considered to have progressed on the date of death. Participants who did not have any baseline or post baseline tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date.
| Months | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Progression Free Survival (PFS) Per Investigator Assessment | 13.77 (11.53 to 15.70) | 12.19 (10.25 to 14.06) |
ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). BOR is defined as the best response designation as determined by BICR per RECIST 1.1, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of subsequent anticancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.
| Percentage of Participants | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) | 60.6 (51.6 to 69.2) | 45.6 (33.5 to 58.1) |
ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). BOR is defined as the best response designation as determined by tumor assessments by the Investigator per RECIST 1.1, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of subsequent anticancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.
| Percentage of participants | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Objective Response Rate (ORR) Per Investigator Assessment | 60.6 (51.6 to 69.2) | 52.9 (40.4 to 65.2) |
Duration of objective response (DoR) is defined as the time between the date of first confirmed complete response (CR) or partial response (PR) to the date of the first documented tumor progression as assessed by the BICR based on RECIST 1.1 criteria or death due to any cause, whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.
| Months | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Duration of Response (DoR) Per Blinded Independent Central Review (BICR) | 12.88 (9.00 to 14.72) | 9.26 (7.49 to 11.30) |
Duration of objective response (DoR) is defined as the time between the date of first confirmed complete response (CR) or partial response (PR) to the date of the first documented tumor progression as assessed by the investigator based on RECIST 1.1 criteria or death due to any cause, whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.
| Months | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Duration of Response (DoR) Per Investigator Assessment | 12.48 (8.87 to 16.72) | 11.07 (9.43 to 17.31) |
Time to objective response (TTR) is defined as the time from the randomization date to the date of the first confirmed complete response (CR) or partial response (PR) as assessed by BICR. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm. TTR is derived for responders only.
| Months | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Time to Objective Response Per Blinded Independent Central Review (BICR) | 2.83 ± 1.51 | 2.83 ± 1.45 |
TTR is defined as the time from the randomization date to the date of the first confirmed complete response (CR) or partial response (PR) as assessed by investigator. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm. TTR is derived for responders only.
| Months | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Time to Objective Response Per Investigator Assessment | 2.83 ± 2.51 | 2.83 ± 1.34 |
Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For those without documentation of death, OS will be censored on the last date the participant was known to be alive.
| Months | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Overall Survival (OS) | 30.52 (25.20 to 39.39) | 31.77 (24.38 to 38.70) |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
| Participants | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 122 | 61 |
Number of participants with any grade of serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine safety and tolerability. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 57 | 20 |
The number of participants who died during the treatment period
| Participants | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Number of Participants Experiencing Death | 87 | 42 |
The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal
| Participants | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| ALT OR AST > 3XULN | 16 | 6 |
| ALT OR AST > 5XULN | 7 | 2 |
| ALT OR AST > 10XULN | 2 | 0 |
| ALT OR AST > 20XULN | 0 | 0 |
| TOTAL BILIRUBIN > 2XULN | 0 | 1 |
| ALP > 1.5XULN | 39 | 20 |
| CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 1.5XULN WITHIN ONE DAY | 2 | 1 |
| CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 1.5XULN WITHIN 30 DAYS | 2 | 1 |
| CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN ONE DAY | 0 | 1 |
| CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN 30 DAYS | 0 | 1 |
The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal
| Participants | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| TSH > ULN | 45 | 23 |
| TSH > ULN WITH TSH <= ULN AT BASELINE | 37 | 16 |
| TSH > ULN WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLN | 20 | 2 |
| TSH > ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN | 11 | 9 |
| TSH > ULN WITH FT3/FT4 TEST MISSING | 14 | 12 |
| TSH < LLN | 25 | 3 |
| TSH < LLN WITH TSH >= LLN AT BASELINE | 22 | 3 |
| TSH < LLN WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN | 13 | 0 |
| TSH < LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN | 8 | 2 |
| TSH < LLN WITH FT3/FT4 TEST MISSING | 4 | 1 |
Disease Control Rate (DCR) is defined as the percentage of participants whose Best Overall Response (BOR) is complete response (CR) or partial response (PR) or stable disease (SD). CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.
| Percentage of participants | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Disease Control Rate (DCR) Per Blinded Independent Central Review (BICR) | 91.3 (85.0 to 95.6) | 83.8 (72.9 to 91.6) |
Disease Control Rate (DCR) is defined as the percentage of participants whose Best Overall Response (BOR) is complete response (CR) or partial response (PR) or stable disease (SD). CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.
| Percentage of participants | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Disease Control Rate (DCR) Per Investigator | 85.8 (85.0 to 95.6) | 77.9 (66.2 to 87.1) |
PFS is the time from randomization to the date of first documented progression, as determined by BICR, or death due to any cause, whichever occurs first. Baseline tumor assessment is defined as tumor scans prior to or on randomization date. Participants who did not have documented progression and did not die or participants who started any subsequent anti-cancer therapy without a prior reported progression were censored on date of last tumor assessment on or prior to initiation of the subsequent anticancer therapy, if any. Participants who died without prior progression were considered to have progressed on the date of death. Participants who did not have any baseline assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) were censored at the randomization date. Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date.
| Months | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR) - Extended Collection | 11.99 (9.99 to 15.74) | 12.02 (10.25 to 13.37) |
Collected over Participants were assessed for all-cause mortality from their randomization to study completion, (up to approximately 58 months). SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 45 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: NIV+mFOLFOX+BEV | 89/127 (70.1%) | 67/123 (54.5%) | 122/123 (99.2%) |
| Arm B: mFOLFOX+BEV | 47/68 (69.1%) | 25/62 (40.3%) | 61/62 (98.4%) |
| Event | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| ColitisGastrointestinal disorders | 9/123 | 0/62 |
| Febrile neutropeniaBlood and lymphatic system disorders | 6/123 | 1/62 |
| SepsisInfections and infestations | 6/123 | 1/62 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/123 | 1/62 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 6/123 | 2/62 |
| Abdominal painGastrointestinal disorders | 5/123 | 3/62 |
| PneumoniaInfections and infestations | 4/123 | 0/62 |
| Intestinal perforationGastrointestinal disorders | 1/123 | 2/62 |
| DeathGeneral disorders | 2/123 | 2/62 |
| DiarrhoeaGastrointestinal disorders | 3/123 | 0/62 |
| Event | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV |
|---|---|---|
| NauseaGastrointestinal disorders | 83/123 | 35/62 |
| FatigueGeneral disorders | 73/123 | 38/62 |
| DiarrhoeaGastrointestinal disorders | 74/123 | 20/62 |
| Peripheral sensory neuropathyNervous system disorders | 45/123 | 28/62 |
| Neuropathy peripheralNervous system disorders | 54/123 | 21/62 |
| ConstipationGastrointestinal disorders | 52/123 | 21/62 |
| VomitingGastrointestinal disorders | 49/123 | 13/62 |
| Decreased appetiteMetabolism and nutrition disorders | 47/123 | 16/62 |
| NeutropeniaBlood and lymphatic system disorders | 45/123 | 14/62 |
| Abdominal painGastrointestinal disorders | 40/123 | 19/62 |
| Age, Continuous(Years) | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV | Total |
|---|---|---|---|
| Mean | 56.8 ± 13.3 | 57.2 ± 11.4 | 56.9 ± 12.7 |
| Sex: Female, Male(Participants) | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV | Total |
|---|---|---|---|
| Female | 57 | 19 | 76 |
| Male | 70 | 49 | 119 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 9 | 16 |
| Not Hispanic or Latino | 108 | 53 | 161 |
| Unknown or Not Reported | 12 | 6 | 18 |
| Race/Ethnicity, Customized(Participants) | Arm A: NIV+mFOLFOX+BEV | Arm B: mFOLFOX+BEV | Total |
|---|---|---|---|
| White | 96 | 57 | 153 |
| Black or African American | 8 | 2 | 10 |
| Asian | 15 | 5 | 20 |
| Other | 6 | 3 | 9 |
| Not Reported | 2 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2018 to primary completion in Feb 2021, 35 months.
Results were first posted in Feb 2022, 1 year after primary completion.
Of 36 phase 2/3 interventional studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 105. This study's 35 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab